First anti-RAGE antibodies were studied, then compounds blocking RAGE from avoiding binding to AGE were found, and their efficacy has been partially demonstrated in Alzheimer’s disease. This evidence concerns the gene AGER and early-onset autosomal dominant Alzheimer disease.